Erasca, Inc. - 8-K Filing

Erasca announces updated Phase 1 data for ERAS-0015 showing high objective response rates in KRAS-mutant tumors and accelerates Phase 3 pancreatic cancer trial to H1 2027. (Items: 8.01 Other Events)

SEC EDGAR ·

Tickers: $ERAS

Read the full article at SEC EDGAR

More Regulatory news